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Inhibition of nerve growth and plasticity in the CNS is to a large part mediated by
Nogo-like signaling, now encompassing a plethora of ligands, receptors, co-receptors
and modulators. Here we describe the distribution and levels of mRNA encoding 11 key
genes involved in Nogo-like signaling (Nogo-A, Oligodendrocyte-Myelin glycoprotein
(OMgp), Nogo receptor 1 (NgR1), NgR2, NgR3, Lingo-1, TNF receptor orphan Y
(Troy), Olfactomedin, Lateral olfactory tract usher substance (Lotus) and membrane-
type matrix metalloproteinase-3 (MT3-MPP)), as well as BDNF and GAPDH. Expression
was analyzed in nine different brain areas before, and at eight time points during
the first 3 days after a strong neuroexcitatory stimulation, caused by one kainic acid
injection. A temporo-spatial pattern of orderly transcriptional regulations emerges that
strengthens the role of Nogo-signaling mechanisms for synaptic plasticity in synchrony
with transcriptional increases of BDNF mRNA. For most Nogo-type signaling genes, the
largest alterations of mRNA levels occur in the dentate gyrus, with marked alterations
also in the CA1 region. Changes occurred somewhat later in several areas of the
cerebral cortex. The detailed spatio-temporal pattern of mRNA presence and kainic
acid-induced transcriptional response is gene-specific. We reveal that several different
gene alterations combine to decrease (and later increase) Nogo-like signaling, as
expected to allow structural plasticity responses. Other genes are altered in the opposite
direction, suggesting that the system prepares in advance in order to rapidly restore
balance. However, the fact that Lingo-1 shows a seemingly opposite, plasticity inhibiting
response to kainic acid (strong increase of mRNA in the dentate gyrus), may instead
suggest a plasticity-enhancing intracellular function of this presumed NgR1 co-receptor.
Keywords: NgR1, Nogo-A, Lotus, Lingo-1, Troy, Lgl1, BDNF, kainic acid
INTRODUCTION
The formation of lasting memories is the result of a large number of interacting mechanisms.
Changes occur on the epigenetic level (Halder et al., 2016), there is formation of new neurons
through neurogenesis (Frisén, 2016; Poo et al., 2016), and there are glial alterations, including white
matter changes. However, there is strong evidence that the final executive representation of a novel
engram is an altered structural pattern of the synaptic network. Synaptic plasticity in the brain
was first demonstrated in response to denervations (Raisman, 1969; Cotman et al., 1973) and later
found to occur also in association with long term potentiation (Yuste and Bonhoeffer, 2001). In vivo
imaging of newly formed postsynaptic sites in rodents suggests that individual synapses can exist for
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FIGURE 1 | The Nogo signaling landscape. The figure illustrates signaling interactions taking place between an upper cell that can be a neuron or an
oligodendrocyte, a lower neuron, an astrocyte (right) and the extracellular compartment (Chondritonin Sulfate Proteo glycan, CSPG). For clarity the lower neuron is
depicted as the receptor side, but it should be noted that the directionality with regard to pre/post and autocrine is not yet clear. Ligands include Nogo A with two
extracellular receptor binding domains, Nogo66 (red right segment) and Nogo-A-∆20 (red left segment), Oligodendrocyte-Myelin glycoprotein (OMgp), both
expressed by neurons and oligodendrocytes, Myelin-Associated Glycoprotein (MAG), expressed only in oligodendroglia, B-lymphocyte stimulator (Blys), expressed in
astrocytes and CSPG present in the extracellular matrix (and on cell membranes, not shown). Main ligand-receptor signaling is indicated by orange arrows, additional
signaling by gray arrows. Receptors include Nogo receptor 1 (NgR1), NgR2 and NgR3, Sphingosine 1 Phosphate Receptor 2 (S1PR2), and Paired
immunoglobulin-like receptor B (PirB). Glycosylphosphatidylinositol (GPI)-anchored Nogo receptors need co-receptors: for NgR1, co-receptors are thought to be
TNF receptor orphan Y (Troy) or p75 (also functioning as the low-affinity neurotrophin receptor), and Lingo-1 (LRR and Ig domain-containing, Nogo
Receptor-interacting protein) or Amphoterin-induced gene and ORF-3 (Amigo-3). Whether Lingo-1 operates in the cell membrane or in the cytoplasm is however not
clear (Meabon et al., 2015). Known modulators of Nogo-like signaling include: a disintegrin and metalloproteinase (Adam 22) that associates with NgR1 and is
presumably integrated in the postsynaptic membrane and linked to Post-Synaptic Density 95 (PSD95). NgR1 facilitates the binding of secreted leucine-rich, glioma
inactivated protein 1 (LgI1) to Adam22, and the Adam22-LgI1 complex inhibits Nogo A signaling. Lateral olfactory tract usher substance (Lotus), binds to NgR1,
thereby inhibiting NgR1-mediated signaling. Lotus does not bind to NgR2 or NgR3. Olfactomedin (also known as pancortin in mice) is a secreted glycoprotein that
reduces the binding of NgR1 to co-receptors p75 and Lingo-1, thereby inhibiting NgR1 signaling. Membrane-type matrix metalloproteinase-3 (MT3-MMP) associates
with NgR1 and cleaves it into a soluble N-terminal ectodomain fraction consisting of amino acids 1-358 (NTF-NgR1) that can bind to, and thus block Nogo, and a
C-termimal fraction (CTF-NgR1) which cannot bind ligands (Designed by L. Olson and T. Karlsson, made by A. Röhl).
years, as required if the altered synaptic pattern is to carry
lasting memories (Yang et al., 2009). Such alterations of synaptic
patterns and the preservation of needed synapses are regulated
by the concerted action of a large number of gene products.
There is a prominent role for nerve growth stimulating factors,
in particular BDNF (Lu et al., 2014), and nerve growth inhibiting
factors, not least the Nogo signaling system. Pioneered by Schwab
and coworkers Nogo-type signaling is now known to encompass
a complex set of ligands, receptors, co-receptors and possible
agonists and antagonists (Schwab, 2010; Ferraro et al., 2011; Sato
et al., 2011; Akbik et al., 2012; Mironova and Giger, 2013) as
summarized in Figure 1.
Nogo receptor 1 (NgR1) is downregulated by increased
neuronal activity (Josephson et al., 2003), and lack of
NgR1 causes ocular dominance plasticity to persist into
adulthood (McGee et al., 2005). We hypothesized that
NgR1 regulates long term memory formation and showed
that overexpression of a NgR1 transgene severely impairs
memory formation (Karlén et al., 2009), dendritic architecture
and spine densities (Karlsson et al., 2016). This is in agreement
with several other groups who have showed altered structural
plasticity and memory effects by modulating Nogo signaling
(Delekate et al., 2011; Wills et al., 2012; Akbik et al., 2013;
Petrasek et al., 2014b; Zemmar et al., 2014; Bhagat et al., 2016;
Zagrebelsky et al., 2017).
We subsequently described how increased neuronal activity,
as induced by kainic acid, upregulates the transcriptional activity
of Nogo receptor 2 (NgR2), NgR3, and the NgR1 antagonist
Lotus immediately following a downregulation of NgR1. We
hypothesized that this would increase local structural synaptic
plasticity in the neuropil, while minimizing the risk of neurite
extensions escaping the local environment (Karlsson et al., 2013).
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Transcription of members in the Nogo family are also regulated
by ECT (Nordgren et al., 2013) and spinal cord injury (Endo
et al., 2009).
Understanding the roles and regulations of genes involved
in Nogo-type signaling should offer multiple opportunities
to develop plasticity-promoting treatments. However, detailed
knowledge about how the many genes now known to be
involved in Nogo-type signaling are regulated by a strong
neuroexcitatory stimulus is lacking. Such knowledge is also
needed to understand the possible roles of Nogo-type signaling
during different phases of memory formation and consolidation.
A deeper understanding would also be relevant to pathologies
such as post-traumatic stress disorder.
Kainic acid can be used as a tool to induce strong neuronal
excitation. Depending on dosing and route of delivery, the
drug has been used to excite neurons, as an excitotoxin, as
well as to model epilepsy (Jonsson, 1980). Here we chose to
use kainic acid as a pharmacological tool to obtain strong,
simultaneous, brain-wide neuronal excitation, while avoiding
prolonged epileptic periods. Several new genes implicated in
Nogo-type signaling have been identified. In this study, we
map the location and activity-dependent temporal and regional
changes in these genes as reflected by regional mRNA levels,
determined by radioactive quantitative in situ hybridization. We
also present higher temporal resolution of previously studied
genes. The findings allow us to provide a longitudinal and
regional overview of 11 out of the identified 19 genes involved
in Nogo-type signaling (Figure 1). In total, nine different brain
areas were examined under normal conditions and during the
first 3 days after a strong neuroexcitatory stimulus. We also
compare the location and time course of these alterations to those
of mRNA encoding BDNF and the housekeeping gene GAPDH.
We find that the patterns of transcriptional alterations of genes
coding for ligands, receptors, co-receptors and modulators differ
between genes and brain areas and over time in a manner that
strengthens a role for Nogo-type signaling as a dynamic, strongly
activity-regulated, plasticity-implicated system.
MATERIALS AND METHODS
Ethics Statement
The experiments were approved by the Stockholm North animal
ethics committee (N580/11).
Animals
Male mice (C57/Bl6) were purchased from Charles-River
(Sulzfeld, Germany) at 12 weeks of age. This strain was chosen
as it is the background strain used (or backcrossed to) for most
of the genetic manipulations including our NgR1 overexpressing
mice. This strain is also the one mostly used in studies of
plasticity, regeneration and behavior. Mice were group housed in
litters of 5/cage with access to food and water ad libitum. All mice
were kept in the same animal room on a 12/12 h light/dark cycle
(lights on 06:00–18:00) and temperature was kept at 22–23◦C
with a relative humidity of 60%. Each cage had a small paper
house and some paper towels for ‘‘enrichment’’.
Kainic Acid Administration
The drug was administrated as a single injection in a dose
that causes strong neuronal activation (30 mg/kg i.p.) without
resulting in significant neuronal loss (Schauwecker and Steward,
1997). Mice were injected in and kept in their home cage for the
rest of the experiment. Following injection, the behavior of the
animals was monitored by two experienced scientists and scored
based on a standardized 6-grade seizure scale (Schauwecker and
Steward, 1997). Only mice graded IV (rearing and falling over)
or V (repeatedly rearing and falling over) were included in the
subsequent analysis. No difference in the seizure scores was seen
between kainic acid groups. The groups receiving the kainic acid
injection is referred to as the induced neuronal activity group.
They were compared to mice without intervention, to investigate
how an episode of strong neuronal activation alters baseline
mRNA levels found in untreated controls.
Tissue Preparation
Mice were sacrificed (by decapitation) at the following time
points; 1 h (n = 7), 2 h (n =6), 4 h (n = 5), 8 h (n = 6), 12 h (n = 5),
16 h (n = 6), 24 h (n = 6) and 72 h (n = 6) after the kainic acid
injection. As a control group, untreated mice (n =13), denoted
‘‘0’’ h, were used. Following dissection, brains were immediately
frozen on dry ice and kept at−80 ◦C until sectioning. Brains were
serially sectioned (section thickness 14 µm) at levels containing
striatum and hippocampus, using a cryostat (Microm).
Quantitative In Situ Hybridization
For in situ hybridization, three sections from a striatum level and
three from a hippocampus level per mouse were used. For each
gene every 20th section was used and all genes were analyzed in
the same cohort of animals. We performed in situ hybridization
as previously described (Dagerlind et al., 1992) using 33P-labeled
oligonucleotide antisense DNA probes. When designing these
probes we first used the UCSC genome browser1) to verify that
the probe only matched the desired mRNA. After confirming
a unique match, we used Mfold (Version 3.2; Mathews et al.,
1999; Zuker, 2003) to verify that the probe was not likely to
form hairpin loops. For each specific mRNA, several probes
were created for different parts of the targeted mRNA. The
oligonucleotide sequences used in the present study are available
from the authors. We analyzed the hybridization patterns of the
candidate oligonucleotide probes before one was chosen for the
experiments (expression patterns were always highly similar for
probes directed at the same transcript, but some probes generated
stronger signals and were chosen for subsequent experiments);
expression patterns were also compared to previously published
data when available.
Following in situ hybridization, slides were put on X-ray film
(Biomax, Eastman Kodak) for 3–28 days (depending on the
strength of expression) before being developed. The films were
digitized using a high resolution scanner (v750 PRO, Epson)
and expression was quantified using an image analysis program
(ImageJ v. 1.32j2). The scanned files were not modified in
1http://genome.ucsc.edu/
2http://rsb.info.nih.gov/ij/
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FIGURE 2 | Scanned images from X-ray film autoradiographs. Examples from in situ hybridization with a 33P-labeled oligonucleotide. These high resolution
scans were used for densitometry of defined areas. Shown is the distribution of radioactivity obtained by hybridization to GAPDH mRNA at two levels of the brain.
Framed areas indicate measured areas of interest at (A) a rostral and (B) a caudal level. 1, Cingulate cortex, 2, Sensory cortex, 3, Retrosplenial cortex, 4, CA1,
5 Lateral CA3, 6, Medial CA3, 7, Dentate Gyrus, 8, Enthorhinal Cortex, 9, Amygdala.
any way prior to analysis. In each run a 14C standard curve
(Amersham) was included and used to convert the measured
expression to linearized data. In total nine areas were examined
with three sections per mouse. A few sections had to be excluded
due to drying of the slides during the hybridization process.
In total over 19,000 manual measurements were collected. For
in situ images shown in Figures 3–7, the raw images were
converted to heatmaps using the standard curve in ImageJ (Péan,
2012). The same settings were used for all images of a specific
gene. Figure 2 shows examples of the original scanned film
results and the measured areas of interest. The nine brain areas
were chosen based on their involvement in plasticity related
events such as memory and cognition. Hippocampus, the dentate
gyrus and amygdala were chosen due to their prominent roles in
memory and due to clear expression of the genes of interest. In
cortex cerebri, we limited analysis to the entorhinal cortex, and
the retrosplenial cortex, due to their involvement in memory,
and the cingulate cortex due to its strong role in emotional
processing. The sensory cortex was included as a region that
should become strongly activated by kainic acid injection, but
presumably be less plastic. All original images are available from
the authors.
Statistics
Data were analyzed using a mixed linear model with Bonferroni
correction for the number of regions analyzed (9). When a
significance between group effects was found, this was followed
up with pairwise testing of all groups to the 0 h group using the
estimatedmarginal means and Bonferroni correction using SPSS.
In the text, the significance presented will refer to the between
group effects if nothing else is stated. For visualization, all data
were normalized to the 0 h group.
RESULTS
Mice were injected with kainic acid in their home cage and
kept for up to 72 h before being sacrificed and processed for
in situ hybridization. There was no difference in the seizure
scores between groups injected with kainic acid (data not
shown). We analyzed the expression of all genes in nine brain
areas connected to emotional processing and memory. For
each gene, the results were normalized to mice without any
treatment, referred to as the ‘‘0 h’’ time point, and all data
are represented as percentage change from 0 h. Thus, we are
comparing how strong neuronal activation by the kainic acid
treatment changes activity of the chosen genes compared to
mice without any intervention. In the following, we will describe
alterations of individual genes. All results are also summarized in
Figures 8, 9.
Activity and Expression Controls: BDNF
and GAPDH
BDNF mRNA
The neurotrophin BDNF is expressed mainly in cortical and
hippocampal brain areas (Ernfors et al., 1990) and of key
importance for brain plasticity (Lu et al., 2014). BDNF mRNA
levels are typically relatively low in the non-perturbed brain.
Validating the current study protocol, we found fast and marked
kainic acid induced increase of BDNF mRNA levels in almost all
investigated areas (Figure 3). A closer look at the time course
revealed that the rise of BDNF mRNA was faster in parts of the
hippocampal formation than in cortical areas with clear increases
1 h after the KA challenge and peak levels after 2 h in the
dentate gyrus and CA1 region. BDNF mRNA levels in medial
and lateral CA3 regions peaked at 8 h. CA1 BDNF mRNA levels
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FIGURE 3 | Three day time course of alterations of BDNF and GAPDH mRNA in response to kainic acid. In this and the following figures, two pairs of
heatmaps, both depicting a control and a kainic acid treated mouse, at a striatal and a dorsal hippocampal level, respectively, are shown för each gene. In each pair
the heatmap from the kainic acid treated animal is chosen at a time after treatment when the most visible effects were noted. Time after treatment is indicated.
Control brain heatmaps are labeled 0 h. The graphs show alterations of mRNA levels relative to untreated controls in response to kainic acid at eight time points in
nine brain areas. Note that to visualize details during the first several hours, the X-axis is non-linear. Mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Color of
asterisks refer to the corresponding brain region.
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 April 2017 | Volume 10 | Article 94
Karlsson et al. Stimulus-Regulation of Eleven Nogo-Signaling/Modulating Transcripts
FIGURE 4 | Three day time course of alterations of OMgp and Nogo-A mRNA in response to kainic acid. For legend, see Figure 3.
had returned to baseline by 8 h; by 24 h, BDNF mRNA levels
in the dentate gyrus, and in the medial and lateral CA3 had also
returned to baseline levels.
Marked increases of BDNF mRNA were also found in several
cortical areas. Interestingly, these changes all peaked at 4 h, hence
2 h later than in the dentate gyrus and CA1. The largest increase
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FIGURE 5 | Three day time course of alterations of NgR1, Troy and
Lingo-1 mRNA in response to kainic acid. For legend, see Figure 3.
was seen in cingulate (>6-fold) and S1 sensory (>4-fold) cortex,
lesser increases were noted in enthorhinal and retrosplenial
cortex. The duration of effects in cortical areas and CA1 was
8 h, as opposed to 12–16 h in CA3 and the dentate gyrus. BDNF
mRNA levels were also increased in amygdala during the first
16 h with a peak at 4 h.
GAPDH mRNA
We used GAPDHmRNA hybridization to serve as an expression
control in all areas of interest. In the non-stimulated brain,
GAPDHmRNA was robustly found in cortical and hippocampal
formation neurons. The levels of GAPDH mRNA did not
change significantly at any time in any area except for a late,
significant 50% increase (p < 0.001) in the dentate gyrus
peaking at 24 h after the kainic acid challenge (Figure 3). This
indicates that overall transcription was not increased due to
treatment.
Neurally Expressed Inhibitory Ligands:
OMgp and Nogo-A
OMgp mRNA
Oligodendrocyte-Myelin glycoprotein (OMgp) is expressed by
both neurons and oligodendroglia and serves as a ligand
for NgR1 and PirB (Wang et al., 2002; Atwal et al., 2008).
Relatively low OMgp mRNA hybridization signals were noted
in most cortical areas, although a stronger signal was noted
in piriform cortex. OMgp mRNA levels were not significantly
altered in either the dentate gyrus or CA3. However, levels
were upregulated in CA1 (76%, p < 0.001) 2 h after kainic
acid administration, after which levels dropped again, reaching
baseline levels by 8 h (Figure 4). The situation was different
in amygdala where mRNA levels remained stable during the
initial part but dropped slightly by 24 h (20% down-regulation,
p = 0.015). Likewise, OMgp mRNA levels were significantly
downregulated in perirhinal and cingulate cortex in the later
phase of the experiment (Figure 4). An overview of all nine
investigated areas shows that the early increase of OMgp mRNA
in CA1 stands out as the most marked effect of kainic acid.
Nogo-A mRNA
This ligand, originally identified in myelin (Caroni and Schwab,
1988), is also expressed by neurons (Josephson et al., 2001).
Unlike OMgp mRNA, Nogo-A mRNA was widely expressed in
the untreated brain and present at higher levels than OMgp
mRNA. Nogo-A mRNA levels were rather stable over time
and across brain areas. However, levels were significantly,
albeit modestly affected in the dentate gyrus and amygdala
(Figure 4). In the dentate gyrus Nogo-A mRNAwas significantly
upregulated between 8 h and 16 h after kainic acid (peak
16 h 88% increase, p < 0.001). In amygdala Nogo-A increased
slowly, reaching a peak upregulation at 16 h (56% increase,
p = 0.007) and then returned to baseline levels by 72 h. Observing
all nine investigated areas, a pattern emerges with a general
modest decrease at 1 h. This is followed by a modest steadily
increase until 16 h after kainic acid, after which there is a
decline of Nogo-AmRNA in all areas towards pretreatment levels
by 72 h.
The NgR1 Signaling Complex: NgR1, Lingo
and Troy
NgR1 mRNA
NgR1 was the first identified Nogo receptor (Fournier et al.,
2001), and binds the Nogo66 segment of Nogo, as well as
OMgp (Wang et al., 2002) and MAG (Liu et al., 2002).
Its expression is exclusively neuronal (Fournier et al., 2001;
Josephson et al., 2002). As expected, we find robust, gray
matter-specific expression of NgR1mRNA in cerebral cortex,
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FIGURE 6 | Three day time course of alterations of NgR2 and NgR3 mRNA in response to kainic acid. For legend, see Figure 3.
amygdala, habenula and the hippocampal formation of untreated
animals. Lesser amounts of NgR1 mRNA were found in
thalamus, while striatum did not express detectable amounts
of NgR1 mRNA. NgR1 mRNA levels were found to be
significantly altered in two regions, the hippocampal CA1 area,
and the dentate gyrus (Figure 5). In CA1, levels had declined
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FIGURE 7 | Three day time course of alterations of Olfactomedin,
Lotus and MT3-MMP mRNA in response to kainic acid. For legend, see
Figure 3.
already at the first studied time point, 1 h, and continued to
drop until 4 h when levels were down by 52% (p = 0.002).
Expression of NgR1 mRNA in CA1 had returned to baseline
levels at the 8 h timepoint, and no further significant changes
were seen in CA1. In the dentate gyrus, NgR1 mRNA levels
also decreased during the early phase and thus mirrored
changes in CA1, but with a slightly faster time course and
larger amplitude. Expression was significantly downregulated
at 1 h (p = 0.014) and a maximal down-regulation was seen
after 2 h when there was a 55% reduction of mRNA levels
FIGURE 8 | Heat map of kainic acid-induced changes of mRNA levels
as transcribed from all 13 investigated genes in the dentate gyrus,
CA1, medial and lateral CA3 and amygdala. Changes are expressed as
percent of control levels 1–72 h after kainic acid. Colors indicate degree of
increase (warmer colors) or decrease (colder colors). Note e.g., that the
dentate is more affected by kainic acid than other areas, both in terms of
increased and decreased levels of mRNA species.
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FIGURE 9 | Heat map of kainic acid-induced changes of mRNA levels
as transcribed from all 13 investigated genes in cingulate,
retrosplenial, entorhinal and sensory cortex. Changes are expressed as
percent of control levels 1–72 h after kainic acid. Colors indicate degree of
increase (warmer colors) or decrease (colder colors). Note e.g., that BDNF
mRNA is strongly increased in all cortical areas 2–4 h after kainic acid, while
NgR1 is slightly below 100% in 31 of the 32 data points. For color code, see
Figure 8.
(p < 0.001) lasting until 4 h. In contrast to what was found
in CA1, the NgR1 mRNA signal then increased markedly in
the dentate gyrus, overshooting the baseline level by 53% at
8 h (p < 0.001), whereafter the level remained upregulated
at least until the 24 h timepoint. Hence the duration of the
decrease of NgR1 mRNA in the dentate gyrus was 4 h, while
the following increase lasted at least 24 h and possibly much
longer.
By and large, all four analyzed cortical areas, cingulate,
enthorinal, retrosplenial and sensory cortex, undergo a modest
but not significant decrease of NgR1 mRNA. This is similar to
that noted for CA1, CA3 and amygdala, although NgR1 mRNA
levels in cortical areas appear not to have returned to pre-kainic
acid levels at 72 h (31 of 32 measured time points in cortical
areas are <100%, Figure 9). When changes of NgR1 mRNA
levels of all investigated areas are summarized, the dentate
gyrus stands out with a rapid decrease of Ngr1 mRNA levels,
followed by a marked, lasting increase well above baseline,
a pattern not seen in any other investigated brain area
(Figure 5).
Lingo-1
Being GPI-linked to the cell membrane, the NgRs depend on
co-receptors for signaling. Lingo-1 has been identified as a
NgR1 co-receptor, interacting with another co-receptor, p75 and
NgR1 (Mi et al., 2004). However, more recent work questions the
site of action of Lingo-1, suggesting an intracellular role instead
(Meabon et al., 2015). Untreated mice had robust presence of
mRNA encoding the presumed NgR1 co-receptor Lingo-1 in
cerebral cortex (Figure 5) and in CA1 and CA3, while the
granule cell layers in the dentate gyrus had a lower expression
of Lingo-1 mRNA. The strongest hippocampal expression was
seen in CA3 (Figure 5). Strikingly, Lingo-1 mRNA expression
levels were significantly increased in six out of nine regions by
the kainic acid challenge. The most profound relative change was
seen in the dentate gyrus were mRNA was strongly upregulated
at all time points after KA stimulation, peaking at 8 h (771%
upregulation, p < 0.001). It should be noticed, however, that
this almost eight-fold increase can be partly explained by the
very low pre-kainic acid levels of Lingo-1 mRNA in the dentate
gyrus. The same pattern of upregulation was seen in investigated
hippocampal CA areas, all three of which showed a significant
upregulation 8 h after stimulation. The magnitude and time
course of upregulation was greatest in medial CA3 (165% at
8 h, 74% at 16 h) and lowest in CA1 (96% at 8 h, 54% at
16 h). An upregulation of Lingo-1 was also seen in amygdala
(p = 0.001) with a time course and magnitude similar to that
seen in hippocampus. Lingo-1 was also significantly upregulated
in cingulate cortex but the time course was a bit slower than in
previously mentioned areas, with a maximum reached at 12 h
(54%, p = 0.001).
Troy
We next assessed TNF receptor orphan Y (Troy), a second
co-receptor for NgR1 (Park et al., 2005) that can replace
p75. In untreated mice, Troy mRNA was present in the
hippocampal formation, cerebral cortex and in many subcortical
brain areas. We found Troy mRNA levels to be significantly
altered in three regions (Figure 5). Like NgR1, Troy mRNA
was rather rapidly downregulated in the dentate gyrus by
kainic acid, significantly so at 2 h (41% downregulation,
p = 0.02). Surprisingly, Troy mRNA levels in the dentate gyrus
demonstrated a bi-phasic down/up regulation pattern, returning
to baseline or above by 4 h, before being down-regulated again at
8 h (45%, p < 0.001). In hippocampus Troy mRNA levels were
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significantly decreased in all CA subregions with around 30%
between 2 h and 8 h, and with the changes in medial CA3 lasting
slightly longer and remaining significant at the 12 h timepoint.
There were no significant changes in the individual cortical
areas examined, or in amygdala. However, an overall view of
the nine analyzed areas suggest general modest downregulation
of Troy mRNA, and no robust indication of upregulation above
baseline levels in any investigated brain area.
Homologous NgR1 Receptors: NgR2 and
NgR3
NgR2
Less is known about ligands and co-receptors for the
NgR1 related receptors NgR2 and NgR3. NgR2, however,
binds MAG, and with higher affinity than NgR1 (Robak et al.,
2009). In untreated mice, mRNA encoding NgR2 is present
in lower amounts and fewer areas than NgR1 mRNA. There
is a scattered presence of NgR2 mRNA in the inner half of
the cerebral cortex, and a stronger presence in claustrum and
habenula. In the hippocampal formation, CA1 and CA3, but
not CA2, express NgR2 mRNA, as does the dentate gyrus.
The effects of a kainic acid challenge on NgR2 mRNA levels
differed dramatically from those on NgR1 by being upregulated
in seven out of the nine examined brain areas. In the dentate
gyrus, the mRNA level peaked after 8 h (212% upregulation,
p < 0.001) and was significantly elevated from 4 h to 16 h
after kainic acid. NgR2 mRNA levels in hippocampal areas
showed a slightly delayed increase response, after which levels
slowly returned to baseline, similar to levels in the dentate
gyrus. The first significant upregulation was seen 8 h after
kainic acid delivery, and was strongest in medial CA3 (195%,
p < 0.001) and weakest in CA1 (114%, p < 0.001). NgR2 was
also significantly upregulated in entorhinal cortex with a peak
at 12 h (75%, p < 0.001). This is slightly later than the changes
seen in the hippocampal formation, and in the somatosensory
cortex (32% at 8 h, p = 0.028). The hippocampal and cortical
upregulations were mirrored in amygdala with a peak at 8 h
(124%, p < 0.001) and lasting until 16 h after the kainic acid
injection.
NgR3
NgR3 has been reported to function as a CSPG receptor
(Dickendesher et al., 2012). In the untreated mouse, we found
low levels of NgR3 mRNA. Similarly to NgR2, NgR3 mRNA
levels were strongly upregulated in several brain areas following
the strong kainic acid induced increase of neuronal activity.
Similar to NgR2, NgR3 mRNA levels were most strongly
upregulated in the dentate gyrus, also peaked at 8 h (327%,
p < 0.001), and remained significantly upregulated until 16 h.
Upregulation in medial (173%, p < 0.001) and lateral (156%,
p < 0.001) CA3, was also marked, but with a shorter duration
such that expression levels were only upregulated significantly
until the 12 h time point. NgR3 mRNA levels in CA1 remained
stable, with no significant alteration caused by kainic acid.
NgR3 was also significantly upregulated in amygdala 8 h after
kainic acid stimulation (225%, p < 0.001). Thus NgR3 mRNA
levels were increased the longest in the dentate gyrus,
for a shorter time in CA3 and shorter still in amygdala.
NgR3 mRNA levels were not significantly altered in the
individual cortical areas assessed. Nevertheless, an overall view
of all nine investigated brain areas shows that NgR3 mRNA in
eight of them peaks 8 h after kainic acid; only retrosplenial cortex
lacks such a peak.
Inhibitors of Nogo-Signaling: LgI1, Lotus,
Olfactomedin, MT3-MMP
LgI1
When Adam22 is associated with NgR1, this complex attracts
the secreted Adam22 ligand LGI1, leading to blockade of
NgR1 signaling (Thomas et al., 2010; Figure 1). In the untreated
mouse brain, levels of mRNA encoding LGI1 were prominent
in CA3 compartments and the dentate gyrus, with robust levels
also found in the cerebral cortex and amygdala. However, unlike
the situation for all other investigated genes, LGI1 mRNA levels
seemed not to be significantly regulated by kainic acid in either
high- or low-expressing areas (data not shown).
Lotus
By binding to NgR1, Lotus inhibits Nogo-mediated signaling
(Sato et al., 2011). In the untreated mouse brain, Lotus mRNA
is expressed in many areas, including cortex, hippocampus,
the lateral olfactory tract and piriform cortex, but also in
striatum, islands of Calleja, and in many subcortical and brain
stem nuclei. Levels of mRNA encoding Lotus were dramatically
increased in the dentate gyrus with a peak at 8 h (785%,
p < 0.001) and Lotus mRNA remained significantly elevated for
a prolonged period of time. In CA1, Lotus remained close to
baseline until it increased significantly at 72 h (60%, p = 0.012).
In amygdala Lotus had a bi-phasic expression with a peak
at 8 h (77%, p = 0.012) and at 72 h (92%, p = 0.001).
Comparing all investigated areas, the strong and lasting increase
focally in the dentate gyrus stands out, such that the brain
pattern of Lotus activation differs from that of all other genes
investigated.
Olfactomedin
Originally isolated from frog olfactory neuroepithelium (Snyder
et al., 1991), olfactomedin mRNA was later found to be
present in rat and mouse brains, including hippocampus and
the cerebral cortex and given the alternative name pancortin.
This highly conserved, secreted glycoprotein inhibits signaling
by the NgR1 complex (Nakaya et al., 2012). We found
olfactomedin mRNA to be robustly present in many brain areas,
including the cortices, the hippocampal formation and amygdala.
Olfactomedin mRNA is also present in striatum and thalamus.
Interestingly, this gene seems to have much lower expression in
the CA2 area than in other parts of the hippocampus. Following
kainic acid treatment, the Olfactomedin mRNA level in the
dentate gyrus stands out by undergoing a marked, significant
decrease, reaching its lowest level at 4 h, followed by a significant
increase to above baseline levels, peaking at 16 h. This pattern
is very similar to the changes of NgR1 mRNA levels. Strikingly,
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Olfactomedin 1 mRNA levels in all nine investigated brain areas
are decreased below baseline at 24 h.
MT3-MMP
This metalloproteinase associates with NgR1 and cleaves it. The
N-terminal fragment is soluble and can bind to Nogo-A, thus
blocking it from binding to membrane-bound NgR1 (Ferraro
et al., 2011). Messenger RNA encoding MT3-MMP was found in
cortical areas, amygdala, hippocampus, striatum and the reticular
thalamic nucleus of untreated mice. A striking feature of the
MT3-MMP mRNA distribution was that the highest levels were
found in the granule cell layer of the dentate gyrus. Kainic acid
caused MM3-MMP mRNA to be decrease in medial CA3 at
4 h and then increase to a peak level at 8 h. The same pattern,
although smaller in magnitude, was found in the dentate gyrus.
MT3-MMP mRNA levels in the lateral CA3 showed a similar,
even lesser pronounced, and thus non-significant pattern of
alterations. In fact, MT3-MMP mRNA levels were the lowest
at 4 h in eight of the nine investigated areas. In cortical areas
MT3-MMP mRNA levels were largely stable as were levels in
amygdala.
Additional Genes of Interest
Above we have provided detailed information about location
of transcripts and the effects of a strong excitatory stimulus on
the transcriptional activity of 11 selected key genes involved in
Nogo-like nerve growth inhibitory signaling, as well as BDNF
and GAPDH mRNA. We did not observe measurable levels of
mRNA encoding S1PR2, PirB, BlyS or p75 in the chosen areas
of interest. This remained true even after kainic acid treatment.
MAG was not examined due to its very limited expression in the
gray matter. Further, we did not investigate the CSPG group of
proteins.
DISCUSSION
The importance of the inhibitory, plasticity-regulating Nogo-like
signaling system in gray matter during development and
in adulthood has been revealed by studying the effects of
perturbations such as blocking, decreasing, or increasing the
Nogo-NgR signaling pathway, causing increased and decreased
plasticity, respectively (McGee et al., 2005; Park et al., 2006a,b;
Lee et al., 2008; Karlén et al., 2009; Wills et al., 2012; Akbik
et al., 2013; Tews et al., 2013; Petrasek et al., 2014a; Iobbi
et al., 2016; Karlsson et al., 2016; Kellner et al., 2016; Stephany
et al., 2016a,b; Zagrebelsky et al., 2017). Increased levels of
Nogo-A have been reported in schizophrenia (Novak et al.,
2002), multiple sclerosis (Satoh et al., 2005), temporal lobe
epilepsy (Bandtlow et al., 2004) and Alzheimer’s disease (Gil
et al., 2006). An increasing number of mutations and genetic
variants in genes depicted in Figure 1 have been found
coupled to neuropsychiatric and neurodegenerative disorders,
including schizophrenia (NgR1/Nogo-A: Budel et al., 2008; Willi
and Schwab, 2013; Andrews and Fernandez-Enright, 2015),
(LGI1/NgR1: Thomas et al., 2016), ALS (NgR1: Amy et al.,
2015), Pelizaeus-Merzbacher disease (MAG: Lossos et al., 2015),
Parkinson’s disease (Lingo-1: Chen et al., 2015), Tourette
syndrome/OCD/ADHD (Olfactomedin: Bertelsen et al., 2015)
and epilepsy (LgI1: Fukata et al., 2010); (ADAM22: Muona
et al., 2016), further emphasizing the importance of normal
Nogo-type control of synaptic plasticity. Current knowledge has
also led to the initiations of clinical trials in spinal cord injury
(NCT00406016), multiple sclerosis (Ineichen et al., 2017), and
ALS in which disease a large phase II trial shows no positive
effects of Nogo-A antibodies (Meininger et al., 2014).
To better understand temporal and spatial regulation of Nogo
signaling genes, we chose to use a single, strong stimulant, and to
compare global changes of multiple genes in several key brain
areas known to exhibit plastic responses under physiological
conditions. Using this approach, we analyzed the location and
activity-induced regulation of levels of mRNA encoding genes
identified as important for Nogo type signaling in unprecedented
detail. Levels of mRNA representing 11 genes have been
quantified in nine different brain regions each, before and at
eight time points during the first 3 days after a strong induction
of neuronal activity, as compared to mRNA levels in untreated
mice. Kainic acid is a strong neuronal stimulant, and toxic if used
in too high doses or in particularly sensitive mouse strains. It
may also affect non-neuronal cells, such as microglia. Due to its
neuroexcitatory efficacy and as based on a wealth of published
research, we chose kainic acid to cause a strong pan-cerebral
increase of activity in a large number of neurons. It should be
noted that kainic acid will also induce activity by secondary
means such as release of Ca2+ which further increases overall
neuronal activity. Hence, it should not be concluded that the
effects seen on transcription are due only to direct downstream
signaling from kainate receptors, but instead is a summary of the
effects of the induced neuronal activation. The stable expression
of GAPDH indicates that the treatment was not strongly
toxic. Strong upregulation of mRNA encoding BDNF, a key
neurotrophin known to be upregulated by increased neuronal
activity (Zafra et al., 1992; Josephson et al., 2003), and stable
levels of the ‘‘housekeeping’’ gene GAPDH mRNA showed that
activity induced genes were upregulated while basal translation
was rather unaffected. We find striking gene- and brain area
specific differences with respect to alterations ofmRNA encoding
Nogo-signaling genes, reflecting different effects of the strong
neuronal stimulation at the transcriptional level. We compare
the effects of the kainic acid injection to untreated controls.
Using this setup we cannot determine to which extent the
upregulation is due to kainic acid, the saline or the injection itself.
Hence, the changes seen compared to untreated mice should
be interpreted as due to the combined effects of the injection
itself and the kainic acid. Furthermore, while the experiments
were planned such that all animals were taken between 08:00 and
20:00, we did not have controls spanning all time points. Hence
possible gene expression alterations due to circadian rhythm
variations cannot be excluded. However, the fact that most
changes were seen either in the rather narrow time-span of 1–4 h,
or as slower changes in the window of 8–24 h, suggests that
circadian effects, if present, are small, compared to effects of
treatment.
Strong and rapid down-regulation of NgR1 mRNA levels
occurs in the dentate gyrus in response to neuronal activation
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(Josephson et al., 2003; Karlén et al., 2009; Wills et al., 2012;
Karlsson et al., 2013). However, increased power and better time
resolution has now allowed us to discover that NgR1 mRNA
levels in the dentate gyrus are not only rapidly decreased in
response to neural activation, but thereafter markedly increased
well above baseline during a longer phase after kainic acid,
possibly working as a homeostatic regulator. This days-long
upregulation of NgR1 mRNA levels after the kainic acid
challenge was unique to the dentate gyrus. Overall, NgR1 mRNA
levels in all other areas were slightly (but not significantly for
any individual area) decreased after kainic acid. This possibly
suggests a days-long shift towards a temporary status of increased
plasticity of hippocampal CA regions, cerebral cortex and the
amygdala. We found mRNA encoding the proposed NgR1
co-receptor Troy to be widely expressed in neurons similar to
those expressing NgR1 mRNA. Troy mRNA showed a similar
but weaker response to neuronal activity in the dentate gyrus
as compared to NgR1. The decrease of Troy mRNA also
appeared to bemore widespread affecting the entire hippocampal
formation, and with a tendency of decrease in cortical areas
similar to that seen for NgR1 mRNA. General decreases of
Troy mRNA are thus in line with decreases of NgR1 mRNA,
and we hypothesize that this could allow increased synaptic
plasticity.
Lingo-1, the second proposed co-receptor of NgR1,
was strongly and widely upregulated following kainic acid
stimulation in agreement with earlier findings (Trifunovski
et al., 2004). This upregulation is interesting in the light of
downregulation of both Troy and NgR1. A recent study has
suggested that Lingo-1 is in fact an intracellular protein, which
can bind NgR1 (Meabon et al., 2015). Increased intracellular
levels of Lingo-1 may internalize NgR1 and/or inhibit
intracellular NgR1 from inserting into the cell membrane.
This could then contribute to decreased NgR1 mediated
signaling. In combination with decreases in transcription of
NgR1 itself, and of Troy, this could result in effective temporary
silencing of Nogo-like signaling. Again, the magnitude of the
kainic acid-induced change is largest in the dentate gyrus, adding
evidence to a particularly strong role of Nogo-type regulation of
activity-induced plasticity in this region.
The ligands OMgp and Nogo-A show patterns of mRNA
alterations that differ from those of NgR1 and its co-receptors.
OMgp mRNA levels remain rather stable during the first part
of the experiment, except for CA1 where a rapid spike of
OMgp mRNA expression was seen. Unlike OMgp, Nogo-A
mRNA levels start to rise early in amygdala and continue to be
elevated during almost the entire experiment. A few hours later
Nogo-A mRNA becomes strongly upregulated in the dentate
gyrus. This raises the possibility that OMgp and Nogo-A mRNA
increases serve to limit plasticity in CA1 and the dentate gyrus
and amygdala, respectively, immediately after an episode of
strong neuronal activation. It is interesting that the two areas
with the most prominent down-regulation of NgR1 mRNA
levels are the same regions where we detect an upregulation
of OMgp and Nogo-A mRNA levels. A possible explanation is
that early upregulation of the ligands does not in itself activate
NgR1 signaling because NgR1 is downregulated. Instead, it could
be important for limiting later plasticity when transcription of
NgR1 is upregulated. Using our method we cannot determine if
it is the same neurons that upregulate OMgp and Nogo-A that
also downregulate NgR1.
When it comes to NgR1 inhibitors, levels of mRNA encoding
Lotus are massively increased by activity in the dentate gyrus.
Hence, NgR1 could be both transcriptionally repressed and
actively inhibited by its antagonists. It is interesting that an
increase in NgR1 mRNA in the dentate gyrus can be seen
at the same time as Lotus mRNA goes up in this area.
Together with the regulation of the ligands discussed earlier,
it raises interesting questions about how this regulation occurs
on a per cell basis and even at subcellular levels. Lotus
could: (1) counteract the effects of the late NgR1 upregulation;
(2) affect a different cell population than the one that upregulates
NgR1 and Nogo-A; or (3) be active in different neuronal
compartments.
Unexpectedly, the regulatory time profile of Olfactomedin
mRNA levels in the dentate gyrus is similar to that of
NgR1 mRNA. However, the phase of upregulation is not as
long-lasting as that of NgR1 mRNA. While smaller, the changes
inMT3-MMPmirror the changes in OlfactomedinmRNA levels.
It may at first seem counterproductive that NgR1 and antagonists
downregulate together. Our hypothesis is that during the early
stages following activation, NgR1 levels drop strongly in key
cells for the memory trace at hand. However, remaining neurons
that were not (or only weakly) activated retain higher levels of
NgR1 signaling during the early phase. With decreasing levels of
the inhibitor Olfactomedin and the reduced proteolytic cleavage
by MT3-MMP, inhibition should increase in neurons with
high NgR1 levels. Neurons that have strongly downregulated
NgR1 should be less affected.
The secreted protein LgI1 interacts with Adam22, a
membrane protein that anchors to PSD95 (Fukata et al., 2010;
Lovero et al., 2015), and this complex can inhibit NgR1 signaling
(Thomas et al., 2010). Mutations in LgI1 that reduce the levels of
secreted LgI1 (Senechal et al., 2005), cause ‘‘hereditary autosomal
dominant partial epilepsy with auditory features’’ (ADPEAF;
Fukata et al., 2010). Animal studies have shown that lack of
LgI1 causes lethal epilepsy and that LgI1 regulates excitability in
the brain (Fukata et al., 2010). Indeed, mutations of Adam22 has
also been linked to severe epilepsy with cerebral atrophy (Muona
et al., 2016).
We find that LGI1 mRNA levels are high in the dentate gyrus
andCA3, and that lower levels of LgI1mRNA are present in other
hippocampal and cortical areas and amygdala. Unexpectedly,
we did not find any significant alteration of the expression
of LGI1 mRNA after kainic acid administration in any of the
investigated areas (data not shown). The lack of, or minor
alterations of LgI1 mRNA levels, shows that LgI1 differs from
all other examined genes and suggests that LGI1 inhibition
is not significantly regulated by strong neuronal activation. If
LgI1 is not significantly regulated, Adam22, or its binding to
PSD95 might instead be regulating the Adam22-LgI1 complex.
However, our preliminary data have not suggested an activity-
induced regulation of ADAM22mRNA. Together, these findings
suggest that the ADAM22-LgI1 complex, important as it may be
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for regulation of neuronal excitability, is not markedly regulated
by alterations of neuronal activity.
The findings with regard to NgR2 and NgR3 mRNA levels
extend our previous findings (Karlsson et al., 2013) and show
that these two NgR1 receptor analogs are strongly activated by
increased neuronal activity inmost brain areas. The predominant
binding partners to these receptors are MAG (Venkatesh et al.,
2005) and CSPGs (Dickendesher et al., 2012) respectively,
suggesting a role of restricting plasticity to local areas, by
inhibiting plasticity in the presence of myelin or extracellular
matrix scaffolds.
We conclude that 10 of the 11 investigated genes involved
in different ways in Nogo-type signaling respond to neuronal
activation by alterations of mRNA levels during the following
72 h. Each gene is characterized by a unique temporo-spatial
pattern of mRNA alterations. Together, patterns of changes
and the simultaneous alterations of BDNF mRNA levels can
be interpreted as a logical way to temporarily allow optimal
plasticity in certain brain regions and neurons, while not
affecting other neurons and to also effectively lock altered
circuitry of affected neurons in its new conformation, carrying
a new engram.
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